An observational study in Telehealth Services and Telehealth, sponsored by Pei-Hung Liao. Withdrawn. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by Pei-Hung Liao · Observational
Heart failure is associated with high incidence and mortality rates, limited physical activity, decreased quality of life, and increased healthcare expenses. Implementing a Telehealth Care (TC) HF program could address these challenges while improving patient outcomes.
Telemonitoring for heart failure patients reduces all-cause and cardiovascular mortality by enabling early intervention during clinical deterioration, improving outcomes even for those recently discharged. Moreover, a reduction in the percentage of days lost due to unplanned cardiovascular hospital admissions is evident. Furthermore, the rapid expansion of telehealth care and telemedicine services during the COVID-19 pandemic optimized the management and care quality of heart failure patients through telemonitoring .
Pei-Hung Liao is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inpatients diagnosed with heart failure were enrolled, with patients automatically selected daily by the electronic medical record system. A list of ward visits was obtained based on the first three digits of the International Classification of Diseases 10th edition diagnosis codes; the ICD-10 code I50 was applied for selection.
Exclusion Criteria:
mortality and rehospitalization rates
analyze the one-year all-cause mortality and rehospitalization rates in patients with and without telehealth care while examining cardiovascular mortality and rehospitalization rates simultaneously.
Time frame: After discharge one year
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pei-Hung Liao